Daxor (DXR) Stock Price, News & Analysis

Company Overview

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

Key Stats

• Today's Range: $9.00 to $9.00
• 50-Day Range: $7.20 to $9.29
• 52-Week Range: $6.55 to $10.00
• Volume: 81 shs
• Average Volume: 2,828 shs
• Market Capitalization: $43.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.00
• Consensus Rating: Buy

DXR Stock Analysis - Frequently Asked Questions

How have DXR shares performed this year?

Daxor's stock was trading at $7.69 on January 1st, 2025. Since then, DXR stock has increased by 17.0% and is now trading at $9.00.
View the best growth stocks for 2025 here.

How do I buy shares of Daxor?

Shares of DXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Daxor own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Daxor investors own include Merck & Co., Inc. (MRK), Novavax (NVAX), Arbutus Biopharma (ABUS), Abbott Laboratories (ABT), Abiomed (ABMD), Aclaris Therapeutics (ACRS) and

Company Calendar

• Today: 6/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - OUTP/HM CRE
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:DXR
• CIK: 27367
• Web: www.daxor.com
• Phone: 212-244-0555
• Fax: 212-244-0806
• Employees: 37
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $25.00
• High Stock Price Target: $25.00
• Low Stock Price Target: $25.00
• Potential Upside/Downside: +177.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 4,840,000
• Free Float: 1,959,000
• Market Cap: $43.56 million
• Optionable: Not Optionable
• Beta: -0.13